Abstract:What's new? Treatment for higher‐risk non‐muscle invasive bladder cancer involves intravesical immunotherapy with Bacillus Calmette Guérin (BCG). However, disease recurrence and progression frequently occur. Using a murine model, the authors found that, compared with intravesical immunotherapy, systemic immunotherapy results in improved anti‐tumor responses in bladder cancer. They demonstrate that systemic immunity is required for the generation of an optimal BCG response through the establishment of an anti‐tumoral microenvironment, and that the anti‐tumor effects of BCG may be at least partially mediated by trained immunity. The study emphasizes the need to develop immunotherapeutic approaches for bladder cancer that optimize systemic immune responses. Treatment for higher‐risk non‐muscle invasive bladder cancer (NMIBC) involves intravesical immunotherapy with Bacillus Calmette Guérin (BCG); however, disease recurrence and progression occur frequently. Systemic immunity is critical for successful cancer immunotherapy; thus, recurrence of NMIBC may be due to suboptimal systemic activation of anti‐tumor immunity after local immunotherapy. We previously reported that systemically acquired trained immunity (a form of innate immune memory) in circulating monocytes is associated with increased time‐to‐recurrence in patients with NMIBC treated with BCG. Herein, we used a mouse model of NMIBC to compare the effects of intravesical versus intravenous (systemic) BCG immunotherapy on the local and peripheral immune microenvironments. We also assessed whether BCG‐induced trained immunity modulates anti‐tumor immune responses. Compared with intravesical BCG, which led to a tumor‐promoting immune microenvironment, intravenous BCG resulted in an anti‐tumoral bladder microenvironment characterized by increased proportions of cytotoxic T lymphocytes (CTLs), and decreased proportions of myeloid‐derived suppressor cells. Polarization toward anti‐tumoral immunity occurred in draining lymph nodes, spleen, and bone marrow following intravenous versus intravesical BCG treatment. Pre‐treatment with intravesical BCG was associated with increased rate of tumor growth compared with intravenous BCG pre‐treatment. Trained immunity contributed to remodeling of the tumor immune microenvironment, as co‐instillation of BCG‐trained macrophages with ovalbumin‐expressing bladder tumor cells increased the proportion of tumor‐specific CTLs. Furthermore, BCG‐trained dendritic cells exhibited enhanced antigen uptake and presentation and promoted CTL proliferation. Our data support the concept that systemic immune activation promotes anti‐tumor responses, and that BCG‐induced trained immunity is important in driving anti‐tumor adaptive immunity.

Local induction of bladder Th1 responses to combat urinary tract infections

Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection

A highly polarized TH2 bladder response to infection promotes epithelial repair at the expense of preventing new infections

A Dynamic Interplay of Innate Immune Responses During Urinary Tract Infection

Nociceptor Neurons are Involved in the Host Response to Escherichia coli Urinary Tract Infections

Group 3 Innate Lymphoid Cells Protect the Host from the Uropathogenic Escherichia coli Infection in the Bladder

The nature of immune responses to urinary tract infections

Early Increased Urinary IL-2 and IL-10 Levels Were Associated with Development of Chronic UTI in a Murine Model.

Uropathogenic Escherichia coli infection: innate immune disorder, bladder damage, and Tailin Fang II

Direct Detection of Tissue-Resident Bacteria and Chronic Inflammation in the Bladder Wall of Postmenopausal Women with Recurrent Urinary Tract Infection

The C5a/C5aR1 Axis Contributes to the Pathogenesis of Acute Cystitis Through Enhancement of Adhesion and Colonization of Uropathogenic E. coli

MP29-04 IMMUNOMODULATORY ROLES OF ANTIMICROBIAL PEPTIDE LL-37 IN URINARY BLADDER BACTERIAL INFECTION

Uropathogenic Escherichia coli Superinfection Enhances the Severity of Mouse Bladder Infection

ILC2-derived CGRP triggers acute inflammation and nociceptive responses in bacterial cystitis

Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications

Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli

Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy

Α–intercalated Cells Defend the Urinary System from Bacterial Infection

Recurrent infections drive persistent bladder dysfunction and pain via sensory nerve sprouting and mast cell activity

Antigen-Specific CD4 T Cells Are Induced after Intravesical BCG-Instillation Therapy in Patients with Bladder Cancer and Show Similar Cytokine Profiles as in Active Tuberculosis